MitoDys

In February 2014, Mitodys Therapeutics successfully raised £150,000 to fund the initial optimisation and validation of its drug-discovery platform through initial drug prototypes.

The story

MitoDys is a drug-discovery platform, working on a novel approach to treating Parkinson's disease.

MitoDys is headed up by founder Steven Zimmer and a world-class board of scientific and clinical advisors led by Dr David Weiner, a clinician scientist who is a noted expert in Parkinson’s disease, along with a network of academic laboratories and partner CROs.

The lead investor in this round was The Life Neurological Research Trust.

Mito Dys Theraputics Canvas

Where are they now?

We caught up with Mitodys at our event in April and found out about the company's progress:

See current opportunities

Oval Medical Technologies

EIS
Medtech
Oval Medical Technologies have developed a unique self-injector that’s small and easy to use, especially by patients who are frightened of needles.

Acquired

Trading status

£14,160

Average investment

£1,118,647

Total raised

ORP

EIS
Medtech
Simple and reliable tools that help surgeons be more productive and hospitals to save money.

Active

Trading status

£15,465

Average investment

£912,453

Total raised

Natural Immune Products

EIS
FMCG
Natural Immune Products producers of 100% natural, immunity-strengthening drinks for children.

Active

Trading status

£21,619

Average investment

£172,949

Total raised

Mill Residential REIT

Property
First UK residential Real Estate Investment Trust (REIT), aiming to list on a UK stock exchange in December 2014.

Dissolved

Trading status

£30,130

Average investment

£2,199,520

Total raised

Made in Mind

EIS
Technology, Hardware & Equipment
Made in Mind, combining style and utility to design beautiful products for the mobile market, has successfully raised £352,000 from a number of business angels and sophisticated investors on SyndicateRoom.

In Administration

Trading status

£11,355

Average investment

£352,000

Total raised

Invrep

SEIS
Financial Services
Invrep, the company determined to make reporting to investors as straightforward as possible, has successfully closed its SEIS funding round with help from angels and sophisticated investors on SyndicateRoom.

Active

Trading status

£8,824

Average investment

£150,000

Total raised